Lumigan in France: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in France under the regulatory framework of ANSM (Agence nationale de sécurité du médicament et des produits de santé). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- ANSM (Agence nationale de sécurité du médicament et des produits de santé)
- Currency
- EUR
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in France
In France, prescription medications are tightly regulated under several lists (Liste I, Liste II, stupéfiants). Sécurité sociale covers most prescription costs at varying rates depending on the drug. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in France follows the standard rules of ANSM (Agence nationale de sécurité du médicament et des produits de santé).
Pharmacy dispensing
Pharmacies in France are independent owner-pharmacist businesses, marked by the iconic green cross. The pharmacist is a routine medical consultant for minor ailments and triage. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online pharmacy is permitted only via French ARS-authorised pharmacies physically located in France, primarily for non-prescription medication. Tele-consultation has expanded prescription access since 2020. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in EUR
Retail pricing in France depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in France? ▾
In France, prescription medications are tightly regulated under several lists (Liste I, Liste II, stupéfiants). Sécurité sociale covers most prescription costs at varying rates depending on the drug. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of ANSM (Agence nationale de sécurité du médicament et des produits de santé).
Is generic Lumigan available in France? ▾
Authorised generics of Bimatoprost are typically available in France at a lower cost than branded Lumigan, with bioequivalence required by ANSM (Agence nationale de sécurité du médicament et des produits de santé). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in EUR? ▾
Prices in EUR vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in France.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.